---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-036381"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:28:46.071886+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma repositions Dr. Miller as Consulting Senior Medical Director for conflict-of-interest compliance

## Summary
- Dr. Jeffrey Miller ceased as Consulting Chief Medical Officer and Consulting Chief Scientific Officer effective September 16, 2024.
- He commenced as Consulting Senior Medical Director to align with University of Minnesota conflict-of-interest policies.
- The change precedes the Phase I clinical trial of GTB-3650 compound at the University of Minnesota.

## SEC filing metadata
- accession: 0001493152-24-036381
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315224036381/0001493152-24-036381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315224036381/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-036381
- JSON: https://secwatch.observer/filing/0001493152-24-036381.json
- Plain text: https://secwatch.observer/filing/0001493152-24-036381.txt

## Key facts
- Executive change
  Dr. Jeffrey Miller changed role as Consulting Senior Medical Director at GT Biopharma, Inc..
  - Action: ceased serving as Consulting Chief Medical Officer and Consulting Chief Scientific Officer and commenced as Consulting Senior Medical Director
  - Role: Consulting Senior Medical Director
  source text: Effective September 16, 2024, Dr. Jeffrey Miller ceased serving as the Registrant’s Consulting Chief Medical Officer and Consulting Chief Scientific Officer and commenced service as the Registrant’s Consulting Senior Medical Director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315224036381/0001493152-24-036381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.